Latest news with #EHRs
Yahoo
3 days ago
- Health
- Yahoo
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO, May 30, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company's use of AI-driven solutions to advance precision oncology. "At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine." Research highlights include: Oral Presentation (1506): A technology-enabled clinical trial program's impact on patient screening and trial enrollment in 2024 Date/Time: Monday, June 2 from 3:00 PM–6:00 PM CDT Overview: The TIME network utilized algorithmic screening technology combined with nurse match review to screen over 1.28 million patients for clinical trials in 2024, resulting in 573 total consents - an average of 1.57 consents per day. The network's programmatic screening at scale, Tempus nurse review, and rapid activation processes helps increase patient access to trials. Poster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment Date/Time: Saturday, May 31 from 9:00 AM–12:00 PM CDT Overview: Tempus xM, a tumor-naive test, serves as a prognostic tool for monitoring disease recurrence in resected liver-limited mCRC patients treated with upfront systemic therapy. xM demonstrates strong performance in predicting clinical recurrence and relapse-free survival following surgery. Poster Presentation (499/11160): Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients Date/Time: Saturday, May 31 from 1:30 PM–4:30 PM CDT Overview: LLMs show promise for improving abstraction efficiency, converting clinical data from unstructured EHRs into a structured format suitable for analysis. Tempus utilized a two-stage LLM system to abstract critical clinical data of NSCLC patients, achieving high agreement with human abstractors across various data domains. Poster Presentation (148/6532): Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval Date/Time: Sunday, June 1 at 9:00 AM–12:00 PM CDT Overview: Tempus xH, a whole genome sequencing assay for hematologic malignancies, enables highly sensitive detection of KMT2A-PTDs in AML—unlocking access to targeted therapies like revumenib. xH helps identify patients who may benefit from emerging treatments and equips clinicians with the insights they need. Poster Presentation (20/2558): A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Sunday, June 1 at 1:30 PM–4:30 PM CDT Overview: Tempus xM, a tumor-naive test, monitors treatment response by tracking ctDNA dynamics over time. Patients classified as a molecular non-responder at at least one timepoint while on immunotherapy had worse overall survival than molecular responders or patients with no ctDNA detected, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. To learn more about Tempus at ASCO, click here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on Contacts Erin Carronmedia@
Business Wire
3 days ago
- Business
- Business Wire
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company's use of AI-driven solutions to advance precision oncology. 'At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients,' said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. 'We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine.' Research highlights include: Poster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment Date/Time: Saturday, May 31 from 9:00 AM–12:00 PM CDT Overview: Tempus xM, a tumor-naive test, serves as a prognostic tool for monitoring disease recurrence in resected liver-limited mCRC patients treated with upfront systemic therapy. xM demonstrates strong performance in predicting clinical recurrence and relapse-free survival following surgery. Poster Presentation (499/11160): Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients Date/Time: Saturday, May 31 from 1:30 PM–4:30 PM CDT Overview: LLMs show promise for improving abstraction efficiency, converting clinical data from unstructured EHRs into a structured format suitable for analysis. Tempus utilized a two-stage LLM system to abstract critical clinical data of NSCLC patients, achieving high agreement with human abstractors across various data domains. Poster Presentation (148/6532): Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval Date/Time: Sunday, June 1 at 9:00 AM–12:00 PM CDT Overview: Tempus xH, a whole genome sequencing assay for hematologic malignancies, enables highly sensitive detection of KMT2A-PTDs in AML—unlocking access to targeted therapies like revumenib. xH helps identify patients who may benefit from emerging treatments and equips clinicians with the insights they need. Poster Presentation (20/2558): A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Sunday, June 1 at 1:30 PM–4:30 PM CDT Overview: Tempus xM, a tumor-naive test, monitors treatment response by tracking ctDNA dynamics over time. Patients classified as a molecular non-responder at at least one timepoint while on immunotherapy had worse overall survival than molecular responders or patients with no ctDNA detected, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. To learn more about Tempus at ASCO, click here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Yahoo
3 days ago
- Health
- Yahoo
Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting
CHICAGO, May 30, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. The event will take place May 30 - June 3 in Chicago, Illinois. Tempus will present its cutting-edge clinical findings and innovative technologies, highlighting the company's use of AI-driven solutions to advance precision oncology. "At ASCO 2025, we are proud to showcase a diverse portfolio of studies that highlight how our cutting-edge technologies, including tumor-naive and tumor-informed MRD monitoring, whole genomic sequencing for hematologic malignancies, and multi-omic biomarker profiling, are providing clinicians and researchers with actionable insights to personalize treatment and improve outcomes for patients," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are excited to share these advancements and collaborate with the oncology community to shape the future of precision medicine." Research highlights include: Oral Presentation (1506): A technology-enabled clinical trial program's impact on patient screening and trial enrollment in 2024 Date/Time: Monday, June 2 from 3:00 PM–6:00 PM CDT Overview: The TIME network utilized algorithmic screening technology combined with nurse match review to screen over 1.28 million patients for clinical trials in 2024, resulting in 573 total consents - an average of 1.57 consents per day. The network's programmatic screening at scale, Tempus nurse review, and rapid activation processes helps increase patient access to trials. Poster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment Date/Time: Saturday, May 31 from 9:00 AM–12:00 PM CDT Overview: Tempus xM, a tumor-naive test, serves as a prognostic tool for monitoring disease recurrence in resected liver-limited mCRC patients treated with upfront systemic therapy. xM demonstrates strong performance in predicting clinical recurrence and relapse-free survival following surgery. Poster Presentation (499/11160): Evaluation of large language model (LLM)-based clinical abstraction of Electronic Health Records (EHRs) for Non-Small Cell Lung Cancer (NSCLC) patients Date/Time: Saturday, May 31 from 1:30 PM–4:30 PM CDT Overview: LLMs show promise for improving abstraction efficiency, converting clinical data from unstructured EHRs into a structured format suitable for analysis. Tempus utilized a two-stage LLM system to abstract critical clinical data of NSCLC patients, achieving high agreement with human abstractors across various data domains. Poster Presentation (148/6532): Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval Date/Time: Sunday, June 1 at 9:00 AM–12:00 PM CDT Overview: Tempus xH, a whole genome sequencing assay for hematologic malignancies, enables highly sensitive detection of KMT2A-PTDs in AML—unlocking access to targeted therapies like revumenib. xH helps identify patients who may benefit from emerging treatments and equips clinicians with the insights they need. Poster Presentation (20/2558): A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors Date/Time: Sunday, June 1 at 1:30 PM–4:30 PM CDT Overview: Tempus xM, a tumor-naive test, monitors treatment response by tracking ctDNA dynamics over time. Patients classified as a molecular non-responder at at least one timepoint while on immunotherapy had worse overall survival than molecular responders or patients with no ctDNA detected, highlighting the value of xM molecular response monitoring as a tool to guide ICI treatment decisions. To learn more about Tempus at ASCO, click here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus' research and publications; the contributions of Tempus' research and findings to the larger scientific community and the use of Tempus' products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on Contacts Erin Carronmedia@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Time Business News
3 days ago
- Business
- Time Business News
Optimizing Practice Revenue: The Role of Physician Medical Billing Services
In the intricate landscape of healthcare, physicians face the dual challenge of delivering exceptional patient care while managing the complexities of medical billing. Navigating insurance claims, coding regulations, and reimbursement processes can be overwhelming. This is where physician medical billing services come into play, offering specialized solutions to streamline billing operations and enhance financial performance. Physician medical billing services encompass the comprehensive management of billing processes for medical practices. These services handle tasks such as patient registration, insurance verification, coding, claim submission, payment posting, and follow-ups on denied or unpaid claims. By outsourcing these functions, physicians can focus more on patient care, leaving the administrative intricacies to experts. Improved Revenue Cycle Management: Professional billing services ensure accurate and timely claim submissions, reducing the likelihood of denials and accelerating reimbursements. This leads to a more efficient revenue cycle and improved cash flow for the practice. Expertise in Coding and Compliance: Staying updated with the ever-evolving medical coding standards and compliance regulations is crucial. Billing services employ certified coders who are well-versed in ICD-10, CPT, and HCPCS codes, ensuring that claims are compliant and reducing the risk of audits and penalties. Reduced Administrative Burden: Managing billing in-house requires significant time and resources. Outsourcing these tasks allows medical staff to allocate more time to patient care and other critical functions, enhancing overall productivity. Access to Advanced Technology: Many billing services utilize state-of-the-art software that integrates with electronic health records (EHRs), providing real-time analytics and reporting. This technology aids in tracking financial performance and identifying areas for improvement. Scalability and Flexibility: As a practice grows, its billing needs become more complex. Billing services can scale their operations to accommodate increased patient volumes, ensuring consistent and efficient billing Talent When selecting a physician medical billing service, consider the following factors: Experience and Specialization : Choose a provider with a proven track record in handling billing for your specific medical specialty. : Choose a provider with a proven track record in handling billing for your specific medical specialty. Transparency and Reporting : Ensure the service offers detailed reports and maintains open communication regarding financial performance and claim Billers and Coders (MBC) : Ensure the service offers detailed reports and maintains open communication regarding financial performance and claim Billers and Coders (MBC) Compliance and Security : Verify that the provider adheres to HIPAA regulations and employs robust security measures to protect patient data. : Verify that the provider adheres to HIPAA regulations and employs robust security measures to protect patient data. Customer Support: Opt for a service that offers responsive and knowledgeable support to address any concerns promptly. Physician medical billing services play a pivotal role in enhancing the financial health of medical practices. By entrusting billing operations to specialized professionals, physicians can mitigate errors, ensure compliance, and focus on delivering quality patient care. In an era where efficiency and accuracy are paramount, leveraging the expertise of medical billing services is a strategic move toward sustainable practice growth. TIME BUSINESS NEWS
Yahoo
22-05-2025
- Business
- Yahoo
TigerConnect launches CareConduit to unify hospital systems
Unified healthcare communications company TigerConnect has introduced CareConduit, a cloud-native workflow automation platform aimed at unifying fragmented hospital systems and enhancing care communications. The platform addresses the challenge of integrating disparate systems, which has traditionally required substantial IT resources and incurred high costs. CareConduit is engineered to reduce notification fatigue and manual workflow issues by facilitating seamless communication for healthcare professionals. It integrates various hospital systems such as nurse call systems, electronic health records (EHRs), and virtual nursing hardware with workflow automation. This ensures that actionable information is promptly delivered to the appropriate caregiver. The platform is built upon an AI layer, which has enabled the introduction of intelligent features earlier this year and allows for advanced scheduling and workflow automation in future updates. TigerConnect chief product officer Saurin Shah said: 'Many hospitals are experiencing inflated technology costs and clinician burnout and need a solution to truly unify communications across their ecosystem. 'With CareConduit's powerful integration capabilities and cloud-native automated workflow routing, organisations will see faster time to value, reduced costs, and timely and accurate notifications to the right caregivers, allowing clinicians to focus on patient care and improving patient outcomes.' Alongside the launch of CareConduit, TigerConnect has named Anish Arora as vice-president of Product. Arora said: 'I'm looking forward to working with the team to further advance TigerConnect's offerings and help realise our company's vision of unifying communication across the care continuum.' This announcement follows TigerConnect's earlier release of pre-hospital and transfer solutions designed to improve emergency care coordination. These offerings are designed to streamline emergency medical services and transfer workflows, thereby improving patient throughput and outcomes. "TigerConnect launches CareConduit to unify hospital systems" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
